Have a feature idea you'd love to see implemented?
Let us know!
SLS SELLAS Life Sciences Group Inc
Price (delayed)
$0.9285
Market cap
$65.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.69
Enterprise value
$44.79M
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from
Highlights
The quick ratio has soared by 158% from the previous quarter
SLS's EPS has surged by 55% year-on-year and by 25% since the previous quarter
Key stats
What are the main financial stats of SLS
Market
Valuations
Earnings
Shares outstanding
70.38M
Market cap
$65.35M
Enterprise value
$44.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$32.28M
EBIT
-$32.28M
EBITDA
-$31.74M
Free cash flow
-$33.07M
Per share
Balance sheet
Liquidity
EPS
-$0.69
EPS diluted
-$0.69
Free cash flow per share
-$0.48
Book value per share
$0.25
Revenue per share
$0
TBVPS
$0.36
Total assets
$26.51M
Total liabilities
$10.61M
Debt
$576,000
Equity
$15.89M
Working capital
$13.42M
Debt to equity
0.04
Current ratio
2.26
Quick ratio
1.99
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-178.6%
Return on equity
-629.5%
Return on invested capital
N/A
Return on capital employed
-203.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLS stock price
How has the SELLAS Life Sciences Group stock price performed over time
Intraday
0.92%
1 week
-11.57%
1 month
6.47%
1 year
74.24%
YTD
-10.72%
QTD
-10.72%
Financial performance
How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$32.77M
Net income
-$32.28M
Gross margin
N/A
Net margin
N/A
SELLAS Life Sciences Group's net income has increased by 16% YoY and by 6% QoQ
The operating income has grown by 16% YoY and by 6% from the previous quarter
Growth
What is SELLAS Life Sciences Group's growth rate over time
Valuation
What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
3.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS has surged by 55% year-on-year and by 25% since the previous quarter
SLS's price to book (P/B) is 47% lower than its 5-year quarterly average of 7.1
Efficiency
How efficient is SELLAS Life Sciences Group business performance
The company's return on equity has surged by 96% QoQ and by 22% YoY
SELLAS Life Sciences Group's return on assets has increased by 30% QoQ and by 11% YoY
Dividends
What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLS.
Financial health
How did SELLAS Life Sciences Group financials performed over time
The total assets is 150% greater than the total liabilities
The quick ratio has soared by 158% from the previous quarter
SLS's current ratio has soared by 122% since the previous quarter
SELLAS Life Sciences Group's debt is 96% lower than its equity
The debt to equity has soared by 124% YoY but it has plunged by 83% from the previous quarter
SELLAS Life Sciences Group's debt has decreased by 17% QoQ and by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.